NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

April 4, 2024

https://www.globenewswire.com/news-release/2024/04/04/2857656/0/en/NextCure-Appoints-Dr-Rakesh-Dixit-to-Scientific-Advisory-Board.html

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.